CCR7 and urogenital neoplasm: tolDCs induce an anti‐inflammatory phenotype, inhibit T cell activation, protect renal tubular cells, and alleviate kidney damage. They migrate to the injured kidney via CCR7, secrete TGF‐β/IDO1, and promote fatty acid oxidation, lipid metabolism, energy homeostasis, and apoptosis inhibition, while remodeling the immune microenvironment.